New drug hope for fatty liver in diabetes patients
NCT ID NCT07198516
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study will test whether a drug called Henggliejin can improve fatty liver in 149 adults with type 2 diabetes and nonalcoholic fatty liver disease (NAFLD). Participants will take one tablet daily for 48 weeks. The main goal is to see if liver fibrosis risk scores improve. Because this is a small, single-group trial, results are preliminary and not yet conclusive.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Henggliejin (tablet, 10 mg once daily)
- What this could lead to
- If it works, this could point toward a new treatment option for fatty liver in people with type 2 diabetes.
- What could go wrong
- This is a very early, small, single-arm trial with no placebo group, so results may not be conclusive. The drug's safety and effectiveness are not yet established.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETE TYPE 2 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A new MRI technique could see inside the Liver's metabolism without a biopsy
- Gamifying exercise: could a phone app outperform traditional programs for obesity and diabetes?
- Could a common b vitamin tame fatty liver?
- Can your DNA predict how you respond to a diabetes drug?
- Can a sugar test reveal how fatty liver begins in obese adolescents?
- Could a daily dose of citrus fiber tame fatty liver inflammation?